June 2008- Volume 4, Issue 6

June 2008

In this Issue

Automation & Instrumentation

Invitrogen intros cell therapy biz unit

Invitrogen intros cell therapy biz unit

Invitrogen Corp., which has been steadily building its cell therapy expertise, announced in mid-May the formation of a separate cell therapy business unit focused on the specific needs of the clinical cell therapy market.

Promega and GeneCopoeia play tag

Promega and GeneCopoeia play tag

Companies combine HaloTag with human and mouse ORF sequences

Geared up for GPCRs

Geared up for GPCRs

DiscoveRx, Caliper team up on microfluidic, cell-based assay deal targeting GPCR researchers

Putting their ChIPs on the table

Putting their ChIPs on the table

Illumina, Genpathway team up to offer whole-genome ChIP sequencing services

Genomics & Proteomics

Yerkes’ monkey business

Yerkes’ monkey business

Researchers develop first transgenic nonhuman primate model of Huntington’s disease

Oligo-ing above and beyond

Oligo-ing above and beyond

Agilent and Broad team up on genome-partitioning kits

Lipid mania

Lipid mania

Lipidoids offer novel RNAi therapy delivery

Hope springs eternal for Benitec’s IP

Hope springs eternal for Benitec’s IP

City of Hope trial helps Benitec to rebuild its RNAi strength

Cancer cohorts

Cancer cohorts

Researchers around the world launch the International Cancer Genome Consortium

Research & Development

On their own again

On their own again

Pfizer sells cholesterol therapy-focused Esperion Therapeutics

A midnight discovery

A midnight discovery

Minerva stumbles upon cancer therapy breakthrough

Profit for non-profit

Profit for non-profit

SFBR launches for-profit drug company focused on women’s health concerns

UF compound lowers blood pressure

UF compound lowers blood pressure

University of Florida researchers have identified a drug compound that may prevent tissue damage associated with cardiovascular disease, according to a study published in the May 1 edition of the American Heart Association journal Hypertension.

A one-two diabetes punch

A one-two diabetes punch

DiaKine and Kinexum to develop novel combo treatment for type 1 diabetes

Global News

BMS to buy Kosan for $190M

BMS to buy Kosan for $190M

BMS enhances cancer portfolio in two important anti-cancer classes

Takeda strikes deal with Alnylam

Takeda strikes deal with Alnylam

Non-exclusive platform deal could eventually net Alnylam $1 billion

Protecting your genome

Protecting your genome

Congress passes and president signs genetic antidiscrimination bill

Informatics

The fat cell syndicate

The fat cell syndicate

Entelos lends PhysioLab model to Pfizer diabetes consortium

One-stop data shop

One-stop data shop

LabVantage, InforSense integrate data management and analytics platforms

From bedside to bench

From bedside to bench

GenoLogics develops translational research software for Fred Hutchinson Center

Best of both worlds

Best of both worlds

ClinPhone and invivodata align ePRO solutions

Parkinson’s research 2.0

Parkinson’s research 2.0

The Parkinson’s Institute, 23andMe launch Web-based research initiative

Editor's Focus

Strange bedfellows: Bill Gates and Chairman Mao

Strange bedfellows: Bill Gates and Chairman Mao

News recently out of a discussion at the The Royal Society, London, is raising hopes that an effective and affordable cure for malaria is now on the horizon. But what do both Bill Gates and Chairman Mao have to do with this story? Well, plenty, if you follow the thread and history of malaria treatments.

Patent News

Is it difficult to do deals with universities?

Is it difficult to do deals with universities?

Like many things in life, it’s always easy to criticize the other side. So, what is true?

Commentary

Today’s biopharma venture capital challenge: Risk-sharing models versus risk avoidance

Today’s biopharma venture capital challenge: Risk-sharing models versus risk avoidance

In times like these, when the pendulum of fear swings to risk avoidance, biopharma can only develop products that meet both customer needs and Wall Street expectations through innovative, novel product development based on a reconsidered approach to risk management.

Feature

Trials and tribulations

Trials and tribulations

Effective recruiting for clinical trials requires a commitment to educating patients and physicians
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN June 2022 magazine issue front cover

Latest Issue  

• Volume 18 • Issue 6 • June 2022

June 2022

June 2022 Issue